“We continued to build momentum this quarter with strong execution across our clinical development programs for verekitug in severe respiratory diseases,” said Rand Sutherland, MD, Chief Executive Officer of Upstream Bio (UPB). “Notably, in June, we completed enrollment in our Phase 2 trial in severe asthma, with top-line data expected in the first quarter of 2026. We also initiated our Phase 2 trial in COPD in July, marking the start of development in a third major respiratory indication. Additionally, we remain on track to report top-line results from our Phase 2 trial in CRSwNP in the third quarter of this year.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UPB:
- Positive Outlook for Upstream Bio, Inc. Driven by Promising Phase II Study of Verekitug in CRSwNP Treatment
- Promising Outlook for Upstream Bio, Inc. as Verekitug Advances in Inflammatory Conditions
- 3 Best Stocks to Buy Now, 7/23/2025, According to Top Analysts
- Promising Outlook for Upstream Bio: Buy Rating Backed by Innovative CRSwNP Treatment and Strategic Leadership
- Upstream Bio management to meet with Piper Sandler